The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group

By Samelis G.F.   Skarlos D.   Bafaloukos D.   Kosmidis P.   Anagnostopoulos A.   Aravantinos G.   Dimopoulos M.A.  

Urology, Vol. 61, Iss. 6, 2003-06 ,pp. : 1211-1215

Elsevier

Access to resources Recommend Favorite

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer

By Haas N.   Roth B.   Garay C.   Yeslow G.   Entmacher M.   Weinstein A.   Rogatko A.   Babb J.   Minnitti C.   Flinker D.   Gillon T.   Hudes G.  

Urology, Vol. 58, Iss. 1, 2001-07 ,pp. : 59-64

Elsevier

Access to resources Recommend Favorite

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer 2

By McLeod D.   Zinner N.   Tomera K.   Gleason D.   Fotheringham N.   Campion M.   Garnick M.B.   for the Abarelix Study Group  

Urology, Vol. 58, Iss. 5, 2001-11 ,pp. : 756-761

Elsevier

Access to resources Recommend Favorite

The Role of Endothelin in Hormone-Refractory Prostate Cancer

By Zonnenberg B.A.   Voest E.E.  

European Urology Supplements, Vol. 2, Iss. 3, 2003-03 ,pp. : 9-14

Elsevier

Access to resources Recommend Favorite

Revolutions in the Management of Hormone-Refractory Prostate Cancer

By Abrahamsson P.-A.  

European Urology Supplements, Vol. 2, Iss. 3, 2003-03 ,pp. : 1-2

Elsevier

Access to resources Recommend Favorite